Juno Therapeutics Patents BCMA-Specific CARs for Immunotherapy
Summary
Juno Therapeutics, Inc. has published a patent application (US20260109774A1) for chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA) and encoding polynucleotides, published April 23, 2026. The application covers anti-BCMA antibodies, antigen-binding fragments, and genetically engineered cells expressing the CARs for use in adoptive cell therapy. The invention includes human antibodies that compete for BCMA binding with reference antibodies and is directed toward immunotherapy applications including potential cancer treatments.
“Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 246 changes logged to date.
What changed
Juno Therapeutics, Inc. has published a patent application for BCMA-specific chimeric antigen receptors and encoding polynucleotides for immunotherapy applications. The application (US20260109774A1, A1 publication dated April 23, 2026; filing date August 26, 2025; application number 19310817) covers anti-BCMA antibodies, antigen-binding fragments, heavy chain variable regions, single-chain antibody fragments, and genetically engineered cells expressing the CARs for adoptive cell therapy.
Biopharmaceutical and biotechnology companies developing CAR-T or other cell-based therapies targeting BCMA should review this published application to assess potential freedom-to-operate considerations or licensing opportunities. The application names 18 inventors and covers methods of treating conditions associated with BCMA expression using the disclosed receptor technology.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES
Application US20260109774A1 Kind: A1 Apr 23, 2026
Assignee
Juno Therapeutics, Inc.
Inventors
Blythe D. SATHER, Eric L. SMITH, Rupesh AMIN, Aye CHEN, Kimberly HARRINGTON, Collin HAUSKINS, Erik HESS, Cyr DE IMUS, Jon JONES, Audrey OLSHEFSKY, Stefan PONKO, Ruth SALMON, Semih TAREEN, Rebecca WU, Yan CHEN, Steven M. SHAMAH, Csaba PAZMANY, Jui DUTTA-SIMMONS, Mariana Cota STIRNER, Melissa WORKS
Abstract
Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.
CPC Classifications
C07K 16/2878 A61K 39/395 A61K 40/11 A61K 40/31 A61K 40/4215 A61P 35/00 C07K 14/7051 C07K 14/70521 C07K 14/70578 C12N 5/0636 C12Q 1/6848 A61K 38/00 A61K 2039/505 C07K 2317/524 C07K 2317/528 C07K 2317/53 C07K 2317/565 C07K 2317/622 C07K 2317/73 C07K 2319/02 C07K 2319/03 C07K 2319/30 C07K 2319/33 C12N 2510/00
Filing Date
2025-08-26
Application No.
19310817
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.